You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Diabetes and other endocrinal, nutritional and metabolic conditions
  5. Diabetes

Ranibizumab for treating diabetic macular oedema

  • Technology appraisal guidance
  • Reference number: TA274
  • Published:  27 February 2013
  • Last updated:  26 October 2023
  • Guidance
  • Tools and resources
  • Information for the public
  • History

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) Macular oedema (diabetic) - ranibizumab (rapid review of TA237): response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
04 January 2013
(138.28 Kb 40 sec)

Adobe Acrobat reader required.

  Adobe Acrobat reader required.

This page was last updated: 28 December 2012

Back to top